Citations

Showing 10 of 108119 citations.

PMO-30 Corticosteroid-free remission of ulcerative colitis with filgotinib maintenance therapy: post-hoc analysis of the SELECTION study
Morison, Ben, Vermeire, Séverine , Feagan, Brian, Yun, Chohee , Hsieh, Jeremy, Liu, Xiaopeng, Zhao, Sally, Moerch, Ulrik, Sandborn, William J. , Hibi∥, Toshifumi , Vermeire, Séverine , Loftus, Edward V.

Mayo Clinic

Posters | November 7, 2021 | Volume: No volume available | Issue: No issue available | Pages: A92.2-A92

10.1136/gutjnl-2021-bsg.169 Get It

PMO-10 Survey on the use of artificial intelligence in IBD patients in the USA and UK
Patel, Rajan K., Jatale, Raj, Bressler, Brian , Limdi, Jimmy K. , Nigam, Gaurav , Patel, Rajan, Hayee, Bu , Iacucci, Marietta , Farraye, Francis A.

Mayo Clinic

Posters | November 7, 2021 | Volume: No volume available | Issue: No issue available | Pages: A80.1-A80

10.1136/gutjnl-2021-bsg.149 Get It

OMO-3 Safety analysis of filgotinib for ulcerative colitis: Phase 2b/3 selection study and long-term extension results
Morison, Ben, Watanabe, Mamoru , Yun, Chohee , Zhao, Sally, Hsieh, Jeremy, Moerch, Ulrik, Schreiber, Stefan , Zhou, Yan, Rogler, Gerhard , Loftus, Edward V.

Mayo Clinic

Oral | November 7, 2021 | Volume: No volume available | Issue: No issue available | Pages: A6.1-A6

10.1136/gutjnl-2021-bsg.10 Get It

Status Quo and Trends of Intra-Arterial Therapy for Brain Tumors: A Bibliometric and Clinical Trials Analysis
Rechberger, Julian S. , Thiele, Frederic, Rechberger, Julian S , Thiele, Frederic, Daniels, David J.

Mayo Clinic

Pharmaceutics | November 7, 2021 | Volume: 13 | Issue: 11 | Pages: 1885

10.3390/pharmaceutics13111885 | PMID 34834300 Get It

Intra-arterial drug delivery circumvents the first-pass effect and is believed to increase both efficacy and tolerability of primary and metastatic brain tumor therapy. The aim of this update is to report on pertinent articles and clinical trials to better understand the research landscape to date and future directions. Elsevier’s Scopus and ClinicalTrials.gov databases were reviewed in August 2021 for all possible articles and clinical trials of intra-arterial drug injection as a treatment strategy for brain tumors. Entries were screened against predefined selection criteria and various parameters were summarized. Twenty clinical trials and 271 articles satisfied all inclusion criteria. In terms of articles, 201 (74%) were primarily clinical and 70 (26%) were basic science, published in a total of 120 different journals. Median values were: publication year, 1986 (range, 1962–2021); citation count, 15 (range, 0–607); number of authors, 5 (range, 1–18). Pertaining to clinical trials, 9 (45%) were phase 1 trials, with median expected start and completion years in 2011 (range, 1998–2019) and 2022 (range, 2008–2025), respectively. Only one (5%) trial has reported results to date. Glioma was the most common tumor indication reported in both articles (68%) and trials (75%). There were 215 (79%) articles investigating chemotherapy, while 13 (65%) trials evaluated targeted therapy. Transient blood–brain barrier disruption was the commonest strategy for articles (27%) and trials (60%) to optimize intra-arterial therapy. Articles and trials predominately originated in the United States (50% and 90%, respectively). In this bibliometric and clinical trials analysis, we discuss the current state and trends of intra-arterial therapy for brain tumors. Most articles were clinical, and traditional anti-cancer agents and drug delivery strategies were commonly studied. This was reflected in clinical trials, of which only a single study had reported outcomes. We anticipate future efforts to involve novel therapeutic and procedural strategies based on recent advances in the field.
Systematic Review of Technical Variations for Mohs Micrographic Surgery for Melanoma
Krausz, Aimee E. , Higgins, H. William , Sobanko, Joseph F. , Giordano, Cerrene N., McMurray, Stacy L., Golda, Nicholas, Leitenberger, Justin J. , Bar, Anna, Nijhawan, Rajiv I. , Brewer, Jerry D., Baum, Christian L. , Holmes, Todd, Goldman, Glenn D., Bordeaux, Jeremy S. , Carroll, Bryan T. , MacArthur, Kelly M. , Etzkorn, Jeremy R. , Shin, Thuzar M. , Maher, Ian A. , Srivastava, Divya , Miller, Christopher J.

Mayo Clinic

Dermatologic Surgery | November 7, 2021 | Volume: 47 | Issue: 12 | Pages: 1539-1544

10.1097/dss.0000000000003268 | PMID 34743123 Get It

BACKGROUND Mohs micrographic surgery (MMS) for cutaneous melanoma is becoming more prevalent, but surgical technique varies. OBJECTIVE To define variations in published techniques for MMS for melanoma. METHODS AND MATERIALS A systematic review was performed of PubMed, EMBASE, and Scopus databases to identify all articles describing surgical techniques for MMS for melanoma. Technical details were recorded for the preoperative, intraoperative, and postoperative phases of MMS. RESULTS Twenty-four articles were included. Mohs surgeons vary in how they assess clinical margins, how wide a margin they excise on the first MMS layer, and how they process tissue to determine tumor stage and margin clearance during MMS for melanoma. CONCLUSION Mohs micrographic surgery for melanoma is performed with varied surgical techniques. To establish best practices, additional research is necessary to determine how different techniques affect outcomes.
The use of ileal pouch–anal anastomosis in patients with ulcerative colitis from 2009 to 2018
Kröner, Paul T. , Merchea, Amit , Picco, Michael F., Stocchi, Luca , Colibaseanu, Dorin , Kröner, Paul T , Farraye, Francis A.

Mayo Clinic

Colorectal Disease | November 7, 2021 | Volume: 24 | Issue: 3 | Pages: 308-313

10.1111/codi.15985 | PMID 34743378 Get It

AbstractAimThe existing literature was updated, assessing the use of surgery in patients with ulcerative colitis in more recent years.MethodsThis was a retrospective observational study identifying all patients with ulcerative colitis within the National Inpatient Sample, years 2009–2018. All patients with International Classification of Diseases, Ninth and Tenth Revisions, Clinical Modification diagnostic codes for ulcerative colitis were included. The primary outcome was the trend in total number of total abdominal colectomy, proctocolectomy and simultaneous versus delayed pouch construction.ResultsA total of 1 184 711 ulcerative‐colitis‐related admissions were identified. An increase of 18.6% in the number of patients was observed, while the number of surgeries decreased. A total of 40 499 patients underwent total colectomy, annually decreasing from 5241 to 3185. The number of proctocolectomies without pouch decreased from 1191 to 530, while the number of patients undergoing pouch construction decreased from 2225 to 1284. The proportion of patients undergoing initial pouch at time of proctocolectomy decreased from 995 (45%) to 265 (21%), while the proportion of patients undergoing delayed pouch construction in 2018 was 79% (n = 1120).ConclusionSurgery use in ulcerative colitis has decreased in the last decade despite increasing numbers of hospital admissions in patients with this condition. While the overall proportion of patients undergoing pouch construction remained stable, the majority of patients were initially treated with total colectomy and their ileal pouches werre constructed in a delayed fashion.
Changes in peak oxygen uptake (VO 2peak ) following renal transplant: Results after 3‐year follow‐up
Angadi, Siddhartha S. , Bushroe, Cody M., Chakkera, Harini A.

Mayo Clinic

TRANSLATIONAL SPORTS MEDICINE | November 7, 2021 | Volume: 4 | Issue: 6 | Pages: 845-848

10.1002/tsm2.288 Get It

Medullary thyroid cancer with ectopic Cushing's syndrome: A multicentre case series
Koehler, Viktoria Florentine , Fuß, Carmina Teresa , Berr, Christina , Frank‐Raue, Karin, Raue, Friedhelm , Hoster, Eva , Hepprich, Matthias , Pusl, Thomas, Reincke, Martín , Spitzweg, Christine , Kroiß, Matthias , Glands, The German Study Group for Rare Malignant Tumours of the Thyroid and Parathyroid, Koehler, Viktoria F , Berr, Christina M , Reincke, Martin , Kroiss, Matthias , Hoster, Eva , Christ, Emanuel , Glands, The German Study Group for Rare Malignant Tumours of the Thyroid and Parathyroid

Mayo Clinic

Clinical Endocrinology | November 7, 2021 | Volume: 96 | Issue: 6 | Pages: 847-856

10.1111/cen.14617 | PMID 34743368 Get It

AbstractObjectiveEctopic Cushing′s syndrome (ECS) induced by medullary thyroid cancer (MTC) is rare, and data on clinical characteristics, treatment and outcome are limited.DesignRetrospective cohort study in three German and one Swiss referral centres.PatientsEleven patients with MTC and occurrence of ECS and 22 matched MTC patients without ECS were included.MeasurementsThe primary endpoint of this study was the overall survival (OS) in MTC patients with ECS versus 1:2 matched MTC patients without ECS.ResultsThe median age at diagnosis of ECS was 59 years (range: 35–81) and the median time between initial diagnosis of MTC and diagnosis of ECS was 29 months (range: 0–193). Median serum morning cortisol was 49 µg/dl (range: 17–141, normal range: 6.2–18). Eight (73%) patients received treatment for ECS. Treatment of ECS consisted of bilateral adrenalectomy (BADX) in four (36%) patients and adrenostatic treatment in eight (73%) patients. One patient received treatment with multityrosine kinase inhibitor (MKI) to control hypercortisolism. All patients experienced complete resolution of symptoms of Cushing's syndrome and biochemical control of hypercortisolism. Patients with ECS showed a shorter median OS of 87 months (95% confidence interval [95% CI]: 64–111) than matched controls (190 months, 95% CI: 95–285). Of the nine deaths, four were related to progressive disease (PD). Four patients showed PD as well as complications and comorbidities of hypercortisolism before death.ConclusionThis study shows that ECS occurs in advanced stage MTC and is associated with a poor prognosis. Adrenostatic treatment and BADX were effective systemic treatment options in patients with MTC and ECS to control their hypercortisolism. MKI treatment achieved complete remission of hypercortisolism and sustained tumour control in one treated case.
Cover Image, Volume 32, Issue 11
Al‐Ahmad, Amin , Knight, Bradley P. , Tzou, Wendy S. , Yasin, Omar , Padmanabhan, Deepak , Zagrodzky, Jason , Bassiouny, Mohammed, Burkhardt, J. David , Gallinghouse, G. Joseph , Mansour, Moussa , Knight, Bradley P , Tzou, Wendy , Schaller, Robert D. , McLeod, Christopher J. , Natale, Andrea

Mayo Clinic

Journal of Cardiovascular Electrophysiology | November 6, 2021 | Volume: 32 | Issue: 11 | Pages: No page available

10.1111/jce.15283 Get It

Extracorporeal membrane oxygenation in the forensic setting: A series of 19 forensic cases
Layman, Andrew J. , Lin, Peter T. , Layman, Andrew J.

Mayo Clinic

Journal of Forensic Sciences | November 6, 2021 | Volume: 67 | Issue: 1 | Pages: 243-250

10.1111/1556-4029.14918 | PMID 34741312 Get It

AbstractExtracorporeal membrane oxygenation (ECMO) employs vascular cannulation and a gas exchange circuit to provide support to patients with severely compromised cardiopulmonary function. ECMO is often the last intervention taken before death and thus presents a unique challenge to medical examiners. This study describes the characteristics of decedents on ECMO at the time of death, including clinical indications, types of circuit configurations, causes and manners of death, gross findings at autopsy, and therapeutic complications. Files of a regional medical examiner office within an academic medical center were searched for the period between 2013 and 2019. Nineteen cases were identified with a median age of 36 years. The circumstances surrounding the initial presentation included: sudden death, trauma, substance abuse, homicide, therapeutic complication, work‐related injury, drowning, and hypothermia. The underlying causes of death included injury‐related, as well as respiratory and cardiac‐related natural diseases. The time spent on ECMO varied from less than 1 h to 10 months. Complications encountered due to ECMO included cannulation site bleeding, pneumohemopericardium, retroperitoneal hematoma, limb ischemia, clotting, and cannula dislodgement. The patient population likely to receive ECMO has significant overlap with death circumstances likely to be reported to the medical examiner. As ECMO therapy has become increasingly available, it is of importance for medical examiners and death investigators to be familiar with the procedure as well as its limitations. Familiarity with ECMO and its sequelae allows for the proper documentation of postmortem findings and fosters an informed determination of the cause and manner of death.